Q: Why is Injectables CMO important for Hikma?
Hikma's Injectables Contract Manufacturing Organisation (CMO) is a cornerstone of our Injectables business, with a long history of providing manufacturing services to third parties. This has been crucial to our growth and success. Our extensive network of US FDA and EMA-approved facilities across the US (Cherry Hill, NJ; Bedford, OH), Europe (Sintra, Portugal; Pavia, Italy; Goslar, Germany), makes us an ideal partner for global companies seeking consistent, high-quality, multi-geography manufacturing solutions.

Q: What does Hikma Injectables CMO offer? 
Hikma Injectables CMO provides an established network of manufacturing facilities strategically located in the US and Europe. With a capacity exceeding 500 million units annually, these US FDA and EMA approved sites leverage cutting-edge technology to ensure consistency and high-quality across production lines. 
Offering a broad spectrum of forms and sterile technologies, including liquid and lyophilised vials, pre-filled syringes, infusion bags, and ampoules for various formulations, demonstrates our commitment to innovation and excellence. 
Furthermore, our integrated contract manufacturing services and specialised teams provide tailored solutions, from process design to commercial-scale production, solidifying Hikma’s position as a leader in sterile injectable manufacturing.

“Amid global supply chain issues, Hikma is a reliable EU and US based sterile injectable manufacturer for pharmaceutical companies.”

Q: What sets Hikma Injectables CMO apart for our partners?  
Our growing production capacity and advanced capabilities provide a distinct advantage in the competitive sterile manufacturing industry. Unlike smaller or offshore contract manufacturing organisations, Hikma manufactures within the US for the US market and in the EU for the EU, US, and other markets, ensuring compliance with stringent regulatory requirements. At a time when global supply chain challenges are prompting hospitals and pharmaceutical companies to seek reliable partners, Hikma stands out as a trustworthy EU and US based sterile injectable manufacturer. 
Beyond our robust manufacturing operations, what truly distinguishes us from traditional CMOs is our dedicated technical support. Our highly experienced technical teams are committed to optimising every process transferred into our facilities, ensuring efficiency and seamless integration once products reach commercial production. This focus on technical excellence enables us to deliver consistent, high-quality products to our partners. 

Q: How does Hikma effectively manage relationships with multiple CMO partners?
The aim of our CMO strategy is to work closely with a smaller number of partners, rather than serve a high number of customers. We focus on establishing a good working relationship from the outset and have stable teams to ensure continuity for our partners. This has been proven to decrease the impact of the complexity that usually arises from dealing with new projects and partners. 
In addition to this, we have dedicated teams who are fully focused on the third-party products manufactured at our facilities and supporting our CMO partners.

Q: What are the opportunities for Hikma and its partners?
In today’s landscape of scarce injectable capacity, Hikma stands in a privileged position, thanks to both our existing capacity and ongoing expansion projects. Our lyophilisation capacity expansion is particularly significant as it will equip our US and EU facilities with identical equipment, offering partners the flexibility to access the same high-quality capacity across two geographies and choose their preferred manufacturing location. 
 
Q: How can I contact the Injectables CMO team? 
Please contact us via our website https://www.hikma.com/what-we-do/contract-manufacturing/injectables/